LAPTM4A inhibitors encompass a distinct and well-defined chemical category comprising compounds that are that modulate the activity of the LAPTM4A protein (Lysosome-Associated Protein Transmembrane 4 Alpha). This protein plays a pivotal role in intracellular processes associated with lysosomal function and intracellular trafficking. The inhibitors within this class are strategically developed to interact with LAPTM4A in a controlled manner, potentially influencing its biological functions. LAPTM4A is intricately involved in orchestrating processes within the lysosomes, cellular compartments responsible for degrading waste materials and participating in various cellular pathways. By engaging LAPTM4A, these inhibitors have the potential to exert a precise influence over lysosomal processes and the cellular functions governed by them.
The development of LAPTM4A inhibitors often hinges upon their specific chemical structures, engineered to engage with distinct regions of the protein. This strategic interaction aims to perturb LAPTM4A's activity, thus influencing its contributions to intracellular trafficking and lysosomal homeostasis. The design and synthesis of such inhibitors require an in-depth understanding of LAPTM4A's structural characteristics and its pivotal role within cellular mechanisms. Researchers committed to unraveling the intricacies of LAPTM4A inhibitors aspire to unveil insights into the fundamental workings of cellular processes, enriching our comprehension of cellular biology at a molecular level.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine is a well-known lysosomotropic agent that indirectly affects LAPTm4A function by altering lysosomal pH. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Hydroxychloroquine is a lysosomotropic agent that can impact LAPTm4A-related processes by affecting lysosomal pH and function. | ||||||
Lys05 | 1391426-24-6 | sc-507532 | 5 mg | $140.00 | ||
Lys05 is a lysosomotropic compound that targets lysosomal function, potentially impacting LAPTm4A-mediated processes. It has been explored for its effects on lysosomal degradation and autophagy. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 is a compound that inhibits lysosomal proton pumps, affecting lysosomal pH and function. It indirectly influences LAPTm4A-related processes through its impact on lysosomes. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
Concanamycin A is another inhibitor of lysosomal proton pumps, similar to bafilomycin AIts effects on lysosomal pH can impact LAPTm4A-mediated functions. | ||||||
DBeQ | 177355-84-9 | sc-499943 | 10 mg | $330.00 | 1 | |
DBeQ is a compound that inhibits the proteasomal-associated deubiquitinase (DUB) enzyme. While it primarily affects the proteasome, it might have downstream effects on lysosomal pathways involving LAPTm4A. | ||||||
CA-074 | 134448-10-5 | sc-202513 | 1 mg | $315.00 | ||
CA-074 Me is a selective inhibitor of cathepsin B, a lysosomal protease. Its impact on lysosomal degradation might have implications for LAPTm4A-associated functions. |